Published in Pharma Investments, Ventures and Law Weekly, December 18th, 2005
The trial is scheduled to conclude approximately 2 years after the 600th patient enrolls, or around the end of 2007.
Last month, InterMune announced its decision, based on pre-specified criteria in the study protocol, to enroll an additional 200 patients in the trial to increase the likelihood of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.